Peripheral Artery Disease (PAD)

This channel includes news, interventions, and new technology innovations for peripheral artery diease, PAD and critical limb ischemia.

The Rex Medical Revolution rotational atherectomy system incorporates continuous aspiration and has a dual indication for atherectomy and thrombectomy. #VICA19 #VIVA2019

News | Atherectomy Devices

Revolution Rotational Atherectomy System Effective in IDE Experience

November 7, 2019 — The REVEAL FDA investigational device exemption (IDE) trial confirmed a favorable safety and ...

November 11, 2019

The repuncturable Supera vascular mimetic peripheral stent system from Abbott Vascular was shown to manage bulky, heavily calcified CFA disease due to its extreme crush resistance in the VMI-CFA study. #VIVA #VIVA19 #VIVA2019

News | Stents Carotid

Supera Safe to use for Femoral Stenting Versus Surgery in VMI-CFA Trial

November 11, 2019 — Although common femoral artery (CFA) endarterectomy is still considered the gold standard treatment ...

November 11, 2019

News

One-Year Results of the DISAPEAR Registry Positive for Absorb Stent

November 8, 2019 — The Absorb bioresorbable stent (BVS) demonstrated good patency and clinical outcomes in patients with ...

November 08, 2019

News | Stents Bioresorbable

Bioresorbable Stent Shows Good 5-Year Outcomes in ABSORB BTK Trial

November 7, 2019 — Although the Abbott Absorb fully bioresorbable drug-eluting stent (DES) was taken off the market due ...

November 07, 2019

In.Pact Admiral drug-coated balloon (DCB). #VIVA #VIVA19 #VIVA2019

News | Drug-Eluting Balloons

Drug-coated Balloon Maintains Good Outcomes in 4-Year IN.PACT Global Study Data

November 7, 2019 — Real-world, four-year study results of the In.Pact Admiral drug-coated balloon (DCB) demonstrate long ...

November 07, 2019

The AngioDynamics/Eximo Medical B-Laser represents a new atherectomy device. #VIVA2019 #VIVA #VIVA19

News | Atherectomy Devices

No Difference Between Drug-coated Balloons and Plain Balloons After Laser Atherectomy

November 7, 2019 — There was no difference between drug-coated balloons (DCB) vs. plain old balloon angioplasty (POBA) ...

November 07, 2019

The final, long-term, patient-level data for the Cook Medical Zilver PTX drug-eluting stent (DES) were evaluated to determine if there is an increased mortality risk due to paclitaxel, but was no difference was seen in the five-year mortality rates compared to control patients. #VIVA19 #VIVA #VIVA2019

Feature | Stents Peripheral | Dave Fornell, Editor

No Increased Long-Term Mortality for the Paclitaxel-Coated Zilver PTX Stent

November 6, 2019 – The final, long-term, patient-level data for the Cook Medical Zilver PTX drug-eluting stent (DES) ...

November 06, 2019

The Selution SLR, MedAlliance’s novel sirolimus-eluting balloon, #VIVA2019 #VIVA #VIVA19

News | Drug-Eluting Balloons

Safety and Efficacy Sustained Over Two Years in Selution Drug-eluting Balloon First-in-Human Trial

November 6, 2019 – Positive, two-year data from the first-in-human study of Selution SLR, MedAlliance’s novel sirolimus ...

November 06, 2019

Eluvia and Ranger PAD devices from Boston Scientific. #VIVA19 #VIVA2019 #VIVA

News | Peripheral Artery Disease (PAD)

Positive Data for the Ranger Drug-coated Balloon and Eluvia Vascular Stent

November 6, 2019 – Boston Scientific announced positive data for two of its devices within the peripheral drug-eluting ...

November 06, 2019

Viva conference late breaking clinical trials, #VIVA19 #VIVA #VIVA2019

Feature | VIVA

VIVA 2019 Late-breaking Clinical Trials

November 14, 2019 — The results of the 21 late-breaking clinical trials presented for the first time at V ascular ...

November 14, 2019

News | Drug-Eluting Balloons

Philips Introduces New 200mm and 150mm Stellarex 0.035-inch Low-dose Drug-coated Balloons

October 15, 2019 — Royal Philips introduced two new balloons to its Stellarex 0.035-inch low-dose drug-coated balloon ...

October 15, 2019

An independent analysis of Lutonix 035 drug-coated balloon (DCB) patient-level data showed no statistically significant mortality increase. This was one of the first major reviews of trial data for patients who were treated with a paclitaxel coated device used in peripheral vessels following a meta analysis study of paclitaxel device trials published in December 2018 that showed a mortality safety signal. This was a major discussion during the FDA townhall meeting at the #TCT2019.

News | Drug-Eluting Balloons

LEVANT Trial Data Shows Safety of Drug-Coated Balloon Shown

October 10, 2019 — An independent analysis of Lutonix 035 drug-coated balloon (DCB) patient-level data showed no ...

October 10, 2019

News | Stent Grafts

PQ Bypass Granted IDE Approval to Start TORUS SFA Stent Graft Pivotal Study

October 8, 2019 — PQ Bypass Inc. announced it has received full approval of its investigational device exemption (IDE) ...

October 08, 2019

News | Drug-Eluting Balloons

Virtue Sirolimus-Eluting Balloon Earns FDA Breakthrough Device Designation

September 20, 2019 — Orchestra BioMed Inc., in partnership with Terumo Corp. announced the company has secured ...

September 20, 2019

Technology | Atherectomy Devices

Rex Medical Receives 510(k) Clearance for Revolution Peripheral Atherectomy System

September 13, 2019 — Rex Medical L.P. has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for ...

September 13, 2019